Skip to main content
SpringerLink
Log in

Cytokine-neutralizing therapeutic antibodies

  • Chapter
Novel Cytokine Inhibitors

Part of the book series: Progress in Inflammation Research ((PIR))

  • 104 Accesses

Abstract

Monoclonal antibodies (Mabs) offer the potential as useful therapeutic agents because of their high affinity and selectivity for the target antigen. The standard approach in making Mabs has been to immunise rodents, usually mice, with the desired human protein and generate a mouse anti-human IgG through hybridoma technology. Indeed mouse Mabs are used clinically in acute diseases, such as the use of OKT3 (an anti-CD3 Mab) for the treatment of acute rejection episodes following transplantation. The major drawback for these murine Mabs is the high prevalence of anti-mouse antibody responses in the recipient (the so-called HAMA response). This has two consequences: it results in rapid clearance of the Mab and could cause a large immune response if it (or any other murine Mab) was given a second time. Such Mabs are therefore unsuitable for chronic diseases where repeat therapy is required. Immunogenicity can be reduced using human Mabs produced, for example, by phage display or to humanise or CDR graft a mouse antibody. This reduces the number of mouse residues in the Mab to about 12–15%, the vast majority of which are contained in the CDR regions. Such engineered human antibodies are now having a large impact on the treatment of chronic diseases. Although much of the early pioneering work was done with Mabs in different animal systems, the last few years have seen a plethora of clinical studies performed. These advances have resulted in the registration throughout the world of the first of these drugs for a wide range of diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Waage A, Halstensen A, Espevik T (1987) Association between tumor necrosis factor in serum and fatal outcome in patients with meningococcal disease.Lancet1: 355–357

    Article  PubMed  CAS  Google Scholar 

  2. Waage A, Brandtzaeg P, Halstensen A, Kierulf P, Espevik T (1989) The complex pattern of cytokines in serum from patients with meningococcal septic shock.J Exp Med169: 333–338

    Article  PubMed  CAS  Google Scholar 

  3. Girardin E, Grau GE, Dayer JM, Roux-Lombard P, The J5 Study Group, Lambert P-H (1988) TNF and IL-1 in the serum of children with severe infectious purpura.N Engl J Med319: 397–400

    Article  PubMed  CAS  Google Scholar 

  4. Debets JMH, Kampmeijer R, van der Linden M P, Buurman WA, Van der Linden CJ (1989) Plasma TNF and mortality in critically ill sepsis patients.Crit Care Med17: 489–494

    Article  PubMed  CAS  Google Scholar 

  5. Girardin EP, Berner ME, Grau GE, Suter S, Lacourt G, Pauvier L (1990) Serum TNF in newborns at risk for infections. Eur JPediatr149: 645–647

    CAS  Google Scholar 

  6. Cannon JG, Tompkins RG, Gelfand JA, Michie HR, Stanford GG, van der Meer JW, Endres S, Lonnemann G, Corsetti J, Chernow B et al (1990) Circulating IL-1 and TNF in septic shock and experimental endotoxin fever.J Infect Dis161: 79–84

    Article  PubMed  CAS  Google Scholar 

  7. Calandra T, Baumgartner J-D, Grau GE, Wu MM, Lambert PH, Schellekens J, Verhoef J, Glauser MP (1990) Prognostic values of TNF/cachectin, IL-1, interferon-alpha and Interferon-y in the serum of patients with septic shock. Swiss-Dutch J5 Immunoglobulin Study Group. JInfect Dis161: 982–987

    Article  PubMed  CAS  Google Scholar 

  8. Michie HR, Manogue KR, Spriggs DR, Revhaug A, O’Dwyer S, Dinarello CA, Cerami A, Wolff SM, Wilmore DW (1988) Detection of circulating TNF after endotoxin administration.N Engl J Med318: 1481–1486

    Article  PubMed  CAS  Google Scholar 

  9. Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, Hariri RJ, Fahey TJ, Zentella A, Albert JD et al (1986) Shock and tissue injury induced by recombinant human cachectin.Science234: 470–474

    Article  PubMed  CAS  Google Scholar 

  10. Beutler B, Milsark IW, Cerami AC (1985) Passive immunisation against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin.Science229: 869–871

    Article  PubMed  CAS  Google Scholar 

  11. Ashkenazi A, Marsters SA, Capon DJ, Chamow SM, Figari IS, Pennica D, Goeddel DV, Palladino MA, Smith DH (1991) Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin.Proc Natl Acad Sci USA88: 10535–10539

    Article  PubMed  CAS  Google Scholar 

  12. Silva AT, Bayston KF, Cohen J (1990) Prophylactic and therapeutic effects of a monoclonal antibody to TNF in experimental gram-negative shock.J Infect Dis162: 421–427

    Article  PubMed  CAS  Google Scholar 

  13. Opal SM, Cross AS, Kelly NM, Sadoff JC, Bodmer MW, Palardy JE, Victor GH (1990) Efficacy of a monoclonal antibody directed against tumor necrosis factor in protecting neutropenic rats from lethal infection with Pseudomonas aeruginosa.J Infect Dis161: 1148–1152

    Article  PubMed  CAS  Google Scholar 

  14. Walsh CJ, Sugerman HJ, Mullen PG, Carey PD, Leeper-Woodford SK, Jesmok GJ, Ellis EF, Fowler AA (1992) Monoclonal antibody to tumor necrosis factor alpha attenuates cardiopulmonary dysfunction in porcine gram-negative sepsis.Arch Surg127: 138–444; discussion 144–145

    Article  PubMed  CAS  Google Scholar 

  15. Windsor AC, Mullen PG, Walsh CJ, Fisher BJ, Blocher CR, Jesmok G, Fowler AA, Sugarman HJ (1994) Delayed tumor necrosis factor alpha blockade attenuates pulmonary dysfunction and metabolic acidosis associated with experimental gram-negative sepsis.Arch Surg129: 80–89

    Article  PubMed  CAS  Google Scholar 

  16. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A (1987) Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia.Nature330: 662–664

    Article  PubMed  CAS  Google Scholar 

  17. Hinshaw LB, Tekamp-Olson P, Chang ACK, Lee PA, Taylor FB, Murray CK, Peer GT, Emerson TE, Passey RB, Kuo GC (1990) Survival of primates inLD100septic shock following therapy with antibody to tumor necrosis factor (TNFα).Circ Shock30: 279–292

    PubMed  CAS  Google Scholar 

  18. Hinshaw LB, Emerson TE, Taylor FB, Chang ACK, Duerr M, Peer GT, Flournoy DJ, White GL, Kosanke SD, Murray CK et al (1992) LethalStaphylococcusaureus-induced shock in primates: prevention of death with anti-TNF antibody.J Trauma-Injury Infect Crit Care33: 568–573

    Article  CAS  Google Scholar 

  19. Fiedler VB, Loot I, Sander E, Voehringer V, Galanos C, Fournel MA (1992) Monoclonal antibody to tumor necrosis factor-alpha prevents lethal endotoxin sepsis in adult rhesus monkeys.J Lab Clin Med120: 574–88

    PubMed  CAS  Google Scholar 

  20. Cross AS, Opal SM, Palardy JE, Bodmer MW, Sadoff JC (1993) The efficacy of combination immunotherapy in experimentalPseudomonas sepsis. J Infect Dis167: 112–118

    Article  CAS  Google Scholar 

  21. Wayte J, Silva AT, Krausz T, Cohen J (1993) Observations on the role of tumour necrosis factor-alpha in a murine model of shock due toStreptococcuspyogenes.Crit Care Med21: 1207–1212

    Article  PubMed  CAS  Google Scholar 

  22. Zanetti G, Heumann D, Gerain J, Kohler J, Abbet P, Barras C, Lucas R, Glauser MP, Baumgartner JD (1992) Cytokine production after intravenous or peritoneal gram-negative bacterial challenge in mice.J Immunol148: 1890–1897

    PubMed  CAS  Google Scholar 

  23. Martin RA, Silva AT, Cohen J (1993) Effect of anti-TNF treatment in an antibiotic treated murine model of shock due toStreptococcuspyogenes.FEMS Microbial Lett110: 175–178

    CAS  Google Scholar 

  24. Bagby GJ, Plessala KJ, Wilson LA, Thompson JJ, Nelson S (1991) Divergent efficacy of antibody to tumor necrosis factor-α in intravascular and peritonitis models of sepsis.J Infect Dis163: 83–88

    Article  PubMed  CAS  Google Scholar 

  25. Echtenacher B, Falk W, Mannel DN, Krammer PH (1990) Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis.J Immunol145: 3762–3766

    PubMed  CAS  Google Scholar 

  26. Alexander HR, Sheppard BC, Jensen JC, Langstein HN, Buresh CM, Venzon D, Walker EC, Fraker DL, Stovroff MG, Norton JA (1991) Treatment with recombinant human tumor necrosis factor-alpha protects rats against the lethality, hypotension and hypothermia of gram-negative sepsis.J Clin Invest88: 34–39

    Article  PubMed  CAS  Google Scholar 

  27. Glauser MP, Zanetti G, Baumgartner JD, Cohen J (1991) Septic shock: pathogenesis.Lancet338: 732–736

    Article  PubMed  CAS  Google Scholar 

  28. Exley AR, Cohen J, Buurman W, Owen R, Hanson G, Lumley J, Aulakh JM, Bodmer M, Riddell A, Stephens S et al (1990) Monoclonal antibody to TNF in severe septic shock.Lancet335: 1275–1277

    Article  PubMed  CAS  Google Scholar 

  29. Vincent JL, Bakker J, Marecaux G, Schandene L, Kahn RJ, Dupont E (1992) Administration of anti-TNF antibody improves left ventricular function in septic shock patients. Results of a pilot study.Chest 101:810–815

    Article  PubMed  CAS  Google Scholar 

  30. Fisher CJ, Opal SM, Dhainaut JF, Stephens S, Zimmerman JL, Nightingale P, Harris SJ, Schein RM, Panacek EA, Vincent JL et al (1993) Influence of anti-TNF monoclonal antibody on cytokine levels in patients with sepsis.Crit Care Med21: 318–327

    Article  PubMed  Google Scholar 

  31. Abraham E, Wunderink, R, Silverman H, Perl TM, Nasraway S, Levy H, Bone R, Wenzel RP, Balk R, Alfred R et al (1995) Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha Mab Sepsis Study Group.JAMA273: 934–941

    Article  PubMed  CAS  Google Scholar 

  32. Cohen J, Carlet T (1996) INTERSEPT: an international, multicenter placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-a in patients with sepsis. Crit Care Med 24: 1431–1440

    Article  PubMed  CAS  Google Scholar 

  33. Abraham E, Anzueto A, Gutierrez G, Tessler S, San Pedro G, Wunderink R, Dal Nogare A, Nasraway S, Berman S, Cooney R et al (1998) Double blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group.Lancet351: 929–933

    PubMed  CAS  Google Scholar 

  34. Robinson DS, Hamid Q, Ting S, Tsicopoulos A, Barkans J, Bentley AM, Corrigan C, Durham SR, Kay AB (1992) Predominate TH2-like bronchoalveolar T-lymphocyte population in atopic asthma.N Engl J Med326: 298–304

    Article  PubMed  CAS  Google Scholar 

  35. Kay AB Asthma and Inflammation (1991)J Allergy Clin Immunol87: 893–910

    Article  Google Scholar 

  36. Abbas AK, Murphy KM, Sher A (1996) Functional diversity of helper T lymphocytes.Nature383: 787–793

    Article  PubMed  CAS  Google Scholar 

  37. Gleich GJ, Kita H, Adolphson CR (1995) Eosinophils. In: MN Frank, KF Austen, HN Cloman, ER Unanue (eds):Samters immunologic diseases.5th ed. Little Brown Co, Boston, 205–245

    Google Scholar 

  38. Finkelman FD, Katona IM, Urban JF, Snapper CM, Ohara J, Paul WE (1986) Suppres-lion ofin vivopolyclonal IgE responses by monoclonal antibody to the lymphokine B-cell stimulatory factor 1.Proc Nat Acad Sci USA83: 9675–9678

    Article  PubMed  CAS  Google Scholar 

  39. Finkelman FD, Katona IM, Urban JF, Holmes J, Ohara J, Tung AS, Sample JG, Paul WE (1988) IL-4 is required to generate and sustainin vivoIgE responses.J Immunol141: 2335–2341

    PubMed  CAS  Google Scholar 

  40. Fanslow WC, Clifford KN, Park LS, Rubin AS, Voice RF, Beckmann MP, Widmer MB (1991) Regulation of alloreactivityin vivoby IL-4 and the soluble IL-4 receptor.J Immunol147: 535–540

    PubMed  CAS  Google Scholar 

  41. Sato TA, Widmer MB, Finkelman FD, Madani H, Jacobs CA, Grabstein KH, Maliszewski CR (1993) Recombinant soluble murine IL-4 receptor can inhibit or enhance IgE responsesin vivo.J Immunol150: 2717–2723

    PubMed  CAS  Google Scholar 

  42. Maliszewski CR, Sato TA, Davidson B, Jacobs CA, Finkelman FD, Fanslow WC (1994)In vivobiological effects of recombinant soluble IL-4 receptor.Proc Soc Exp Biol Med206: 233–237

    PubMed  CAS  Google Scholar 

  43. Renz H, Enssle K, Lauffer L, Kurrle R, Gelfand EW (1995) Inhibition of allergen-induced IgE and IgG1 production by soluble IL-4 receptor.Int Arch Allergy Immunol106: 46–54

    Article  PubMed  CAS  Google Scholar 

  44. Konig B, Fischer A, Konig W (1995) Modulation of cell-bound and soluble CD23, spontaneous and ongoing IgE synthesis of human peripheral blood mononuclear cells by soluble IL-4 receptor and the partial antagonistic IL-4 mutant protein IL-4 (Y124D).Immunology85: 604–610

    PubMed  CAS  Google Scholar 

  45. Egan RW, Umland SP, Cuss FM, Chapman RW (1996) Biology of IL-5 and its relevance to allergic disease.Allergy51: 71–81

    PubMed  CAS  Google Scholar 

  46. Egan RW, Cuss FM, Umland SP, Chapman RW (1996) Anti-interleukin-5 antibodies as therapeutic agents in asthma and other eosinophilic diseases. In: B Henderson, M Bodmer (eds):Therapeutic modulation of cytokines.CRC Press, Boca Raton, Florida. 237–264

    Google Scholar 

  47. Egan RW, Athwal D, Bodmer MW, Carter JM, Chapman RW, Chou C-C, Cox MA, Emtage JS, Fernandez X, Foran S et al (2000) Sch 55700, a humanised monoclonal antibody to human interleukin-5, blocks eosinophilic responses and hyperreactivity.J Exp Med; in press

    Google Scholar 

  48. Gulbenkian AR, Egan RW, Fernandez X, Jones H, Kreutner W, Kung TT, Payvandi F, Sullivan L, Zurcher JA, Watnick AS (1992) Interleukin-5 modulates eosinophil accumulation in allergic guinea pig lung. AmRev Respir Dis146: 262–265

    Google Scholar 

  49. Kung TT, Stelts D, Zurcher JA, Watnick AS, Jones H, Mauser PJ, Fernandez X, Umland S, Kreutner W, Chapman RW, Egan RW (1994) Mechanism of allergic pulmonary eosinophilia in the mouse.J Allergy Clin Immunol94: 1217–1224

    Article  PubMed  CAS  Google Scholar 

  50. Kung TT, Stelts DM, Zurcher JA, Adams III GK, Egan RW, Kreutner W, Watnick AS, Jones H, Chapman RW (1995) Involvement of IL-5 in a murine model of allergic pulmonary inflammation: prophylactic and therapeutic effect of anti-IL-S antibody. AmJ Respir Cell Mol Biol13: 360–365

    PubMed  CAS  Google Scholar 

  51. Mauser PJ, Pitman A, Witt A, Fernandez X, Zurcher J, Kung T, Jones H, Watnick AS, Egan RW, Kreutner W, Adams III GK (1993) Inhibitory effect of the TRFK-5 anti-IL5 antibody in a guinea pig model of asthma.Am Rev Respir Dis148: 1623–1627

    Article  PubMed  CAS  Google Scholar 

  52. Van Oosterout AJM, Ladenious ARC, Savelkoul HFJ, Van Ark I, Delsman KC, Nijkamp FP (1993) Effect of anti-IL-5 and IL-5 on airway hyperreactivity and eosinophils in guinea pigs.Am Rev Respir Dis147: 548–552

    Google Scholar 

  53. Mauser PJ, Pitman A, Fernandez X, Foran SK, Adams III GK, Egan RW, Chapman RW (1995) Effect of an antibody to IL-5 in a monkey model of asthma.Am J Respir Crit Care Med152: 467–472

    PubMed  CAS  Google Scholar 

  54. Di Giovine FS, Nuki G, Duff G (1988) Tumour necrosis factor in synovial exudates.Ann Rheum Dis47: 768–772

    Article  PubMed  CAS  Google Scholar 

  55. Chu CQ, Field M, Allard S, Ahney E, Feldmann M, Maini RN (1992) Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair.Br J Rheumatol31: 653–661

    Article  PubMed  CAS  Google Scholar 

  56. Alvaro-Gracia JM, Zvaifler NJ and Firestein G (1990) Cytokines in chronic inflammatory arthritis. V. Mutual antagonism between interferon-gamma and tumour necrosis factor-alpha on HLA-DR expression, proliferation, collagenase production and granulocyte macrophage colony-stimulating factor production by rheumatoid arthritis synoviocytes.J Clin Invest86: 1790–1798

    Article  PubMed  CAS  Google Scholar 

  57. MacDonald BR, Gowen M (1992) Cytokines and bone.Br J Rheumatol31: 149–155

    Article  PubMed  CAS  Google Scholar 

  58. Saklatvala J (1986) Tumour necrosis factor a stimulates resorption and inhibits synthesis of proteoglycan in cartilage.Nature322: 547–549

    Article  PubMed  CAS  Google Scholar 

  59. Brennan FM, Maini RN and Feldmann M (1992) TNFα — A pivotal role in rheumatoid arthritis?Br J Rheumatol31: 293–298

    Article  PubMed  CAS  Google Scholar 

  60. Brahn E, Peacock DJ, Banquerigo MN and Lui DY (1992) Effects of TNFα on collagen arthritis.Lymphokine Cytokine Res 11:253–256

    PubMed  CAS  Google Scholar 

  61. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G (1991) Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis.EMBO J 10:4025–4031

    PubMed  CAS  Google Scholar 

  62. Piguet PF, Grau GE, Vesin C, Loetscher H, Gentz R, Lesslauer W (1992) Evolution of collagen arthritis in mice is arrested by treatment with anti-TNF antibody or a recombinant soluble TNF receptor.Immunology77: 510–514

    PubMed  CAS  Google Scholar 

  63. Henderson B, Blake S, Lewthwaite J, Staines N, Harper N, Andrew D, Bodmer M, Higgs G (1991) The effects of monoclonal antibodies to tumour necrosis factor in animal models of chronic arthritis.Br J Pharmacol104: 442P

    Google Scholar 

  64. Williams RO, Feldmann M, Maini RN (1992) Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis.Proc Natl Acad Sci USA89: 9784–9788

    Article  PubMed  CAS  Google Scholar 

  65. Kollias G, Douni E, Kassiotis G, Kontoyiannis D (1999) On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease.Immunol Rev169: 175–194

    Article  PubMed  CAS  Google Scholar 

  66. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P (1993) Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor a.Arthritis Rheum36 (12): 1681–1690

    Article  PubMed  CAS  Google Scholar 

  67. Heath PK (1997) Use of anti-TNFα therapies as potential treatments for rheumatoid arthritis.Rheum Arthritis1: 235–240

    Google Scholar 

  68. O’Dell JR (1999). Anticytokine therapy — a new era in the treatment of rheumatoid arthritis?N Engl J Med340: 310–312

    Article  PubMed  Google Scholar 

  69. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.N Engl J Med340: 253–259

    Article  PubMed  CAS  Google Scholar 

  70. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breed-veld FC, Macfarlane JD, Bijl H et al (1994) Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor a (cA2) versus placebo in rheumatoid arthritis.Lancet344: 1105–10

    Article  PubMed  CAS  Google Scholar 

  71. Rankin EC, Choy EH, Kassimos D, Kingsley GH, Sopwith AM, Isenberg DA, Panayi GS (1995) The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis.Br J Rheumatol34: 334–342

    Article  PubMed  CAS  Google Scholar 

  72. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K et al (1997) Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.N Engl J Med337: 141–147

    Article  PubMed  CAS  Google Scholar 

  73. Queen C, Schneider WP, Selick HE, Payne PW, Landolfi NF, Duncan JF, Avdalovic AN, Levitt M, Junghans RP, Waldmann TA (1989) A humanised antibody that binds to the interleukin 2 receptor.Proc Natl Acad Sci USA86: 10029–10033

    Article  PubMed  CAS  Google Scholar 

  74. Amlot PL, Rawlings E, Fernando ON, Griffin PJ, Heinrich G, Schreier MH, Castaigne JP, Moore R and Sweny P (1995) Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation.Transplantation60: 748–756

    Article  PubMed  CAS  Google Scholar 

  75. Theze J, Alzari PM, Bertoglio J (1996) Interleukin 2 and its receptors: recent advances and new immunological functions.Immunology Today17: 481–486

    Article  PubMed  CAS  Google Scholar 

  76. Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, Neylan J, Wilkinson A, Ekberg H, Gaston R et al (1998) Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group.N Engl J Med338: 161–165

    Article  PubMed  CAS  Google Scholar 

  77. Nashan B, Light S, Harde IR, Lin A, Johnson JR (1999) Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group.Transplantation67: 110–115

    Article  PubMed  CAS  Google Scholar 

  78. Kovarik JM, Rawlings E, Sweny P, Fernando O, Moore R, Griffin PJ, Fauchald P, Albrechtsen D, Sodal G, Nordal K et al (1996) Prolonged immunosuppressive effect and minimal immunogenicity from chimeric (CD25) monoclonal antibody SDZ CHI 621 in renal transplantation.Transpl Proc28: 913–914

    CAS  Google Scholar 

  79. Kovarik J, Wolf P, Cisterne JM, Mourad G, Lebranchu Y, Lang P, Bourbigot B, Cantarovich D, Girault D, Gerbeau C et al (1997) Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts.Transplantation64: 1701–1705

    Article  PubMed  CAS  Google Scholar 

  80. Kahan BD, Rajagopalan PR, Hall M (1999) Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric antiinterleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group.Transplantation67: 276–284

    Article  PubMed  CAS  Google Scholar 

  81. Maury CPJ, Teppo AM (1987) Raised serum levels of cachectin/tumor necrosis factor alpha in renal allograft rejection.J Exp Med166: 1132–1137

    Article  PubMed  CAS  Google Scholar 

  82. Tilg H, Vogel W, Aulitzky WE, Herold M, Konigsrainer A, Margreiter R, Huber C (1990) Evaluation of cytokines and cytokine-induced secondary messages in sera of patients after liver transplantation.Transplantation49: 1074–1080

    Article  PubMed  CAS  Google Scholar 

  83. Chollet-Martin S, Depoix JP, Uvass U, Pansard Y, Vizzuzaine C, Gougerot-Pocidalo MA (1990) Raised plasma levels of tumor necrosis factor in heart allograft rejection.Transplant Proc22: 283–286

    PubMed  CAS  Google Scholar 

  84. Grewal, HP, Kotb M, Salem A, el Din AB, Novak K, Martin J, Gaber LW, Gaber AO (1993) Elevated tumor necrosis factor levels are predictive for pancreas allograft transplant rejection.Transplant Proc25: 132–135

    PubMed  CAS  Google Scholar 

  85. Holler E, Kolb HJ, Moller A, Kempeni J, Liesenfeld S, Pechumer H, Lehmacher W, Ruckdeschel G, Gleixner B, Riedner C et al (1990) Increased serum levels of tumor necrosis factor a precede major complications of bone marrow transplantation.Blood75: 1011–1016

    PubMed  CAS  Google Scholar 

  86. Piguet PF, Grau GE, Allet B, Vassalli P (1987) Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease.J Exp Med166: 1280–1289

    Article  PubMed  CAS  Google Scholar 

  87. Shalaby MR, Fendly B, Sheehan KC, Schreiber RD, Ammann A J (1989) Prevention of the graft-versus-host reaction in newborn mice by antibodies to tumor necrosis factor-alpha.Transplantation47: 1057–1061

    Article  PubMed  CAS  Google Scholar 

  88. Herve P, Flesch M, Tiberghien P, Wijdenes J, Racadot E, Bordigoni P, Plouvier E, Stephan JL, Bourdeau H, Holler E et al (1992) Phase I-II trial of a monoclonal antitumor necrosis factor a antibody for the treatment of refractory severe acute graft-versus-host disease.Blood79: 3362–3368

    PubMed  CAS  Google Scholar 

  89. Imagawa DK, Millis JM, Seu P, Olthoff, KM, Hart J, Wasef E, Dempsey RA, Stephens S, Busuttil RW (1991) The role of tumor necrosis factor in allograft rejection.Transplantation51: 57–62

    Article  PubMed  CAS  Google Scholar 

  90. Seu P, Imagawa DK, Wasef E, Olthoff KM, Hart J, Stephens S, Dempsey RA, Busuttil RW (1991) Monoclonal anti-tumor necrosis factor-a antibody treatment of rat cardiac allografts: synergism with low-dose cyclosporine and immunohistological studies.J Surg Res50: 520–528

    Article  PubMed  CAS  Google Scholar 

  91. Bolling SF, Kunkel SL, Lin H (1992) Prolongation of cardiac allograft survival in rats by anti-TNF and cyclosporin combination therapy.Transplantation53: 283–286

    Article  PubMed  CAS  Google Scholar 

  92. Stevens HPJD, Van der Kwast TH, Van der Meide PH, Vuzevski VD, Buurman WA, Jonker M (1990) Synergistic immunosuppressive effects of monoclonal antibodies specific for interferon-gamma and tumor necrosis factor alpha. A skin transplantation study in the rhesus monkey.Transplantation50: 856–861

    Article  PubMed  CAS  Google Scholar 

  93. Choy MY, Walker-Smith JA, Williams CB, MacDonald TT (1990) Differential expression of CD25 (interleukin-2 receptor) onlamina propriaT cells and macrophages in the intestinal lesions in Crohn’s disease and ulcerative colitis.Gut31: 1365–1370

    Article  PubMed  CAS  Google Scholar 

  94. Targan SR, Deem RL, Shanahan F (1990) Immune-mediated cytotoxicity in inflammatory bowel disease.Trends Inflam Bowel Dis Ther Falk Symp29–40

    Google Scholar 

  95. Shorter RG, Cardoza MR, ReMilne SG, Spencer RJ, Huizinga KA (1970) Modification ofin vitrocytotoxicity of lymphocytes from patients with chronic ulcerative colitis or chronic granulomatous colitis for allogenic colon epithelial cells.Gastroenterology58: 692–698

    PubMed  CAS  Google Scholar 

  96. Hibi T, Ohara M, Toda K, Ogata H, Iwao Y, Watanabe N, Watanabe M, Hamada Y, Kobayashi K et al (1990)In vitroanticolon antibody production by mucosal or peripheral blood lymphocytes from patients with ulcerative colitis.Gut31: 1371–1376

    Article  PubMed  CAS  Google Scholar 

  97. Glebmann CM, Barrett KE (1993) Role of inflammatory cell types. In: J Scholmerich, W Kruis, H Goebell, W Hohenberger, V Gross (eds):Inflammatory bowel diseases. Pathophysiology as basis of treatment.Kluwer Academic, Dordrecht, Netherlands, 62–79

    Google Scholar 

  98. Plevy SE, Targan SR, Andus T, Toyoda H (1994) Differentiation of Crohn’s disease from ulcerative colitis mucosal inflammation by levels of TNF-α mRNA.Gastroenterology104: part 2, A764

    Google Scholar 

  99. Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT (1993) Location of tumour necrosis factor α by immunohistochemistry in chronic inflammatory bowel disease.Gut34: 1705–1709

    Article  PubMed  CAS  Google Scholar 

  100. Cappello M, Keshav S, Prince C, Jewell DP, Gordon S (1992) Detection of mRNAs for macrophage products in inflammatory bowel disease byin situhybridisation.Gut33: 1214–1219

    Article  PubMed  CAS  Google Scholar 

  101. Steffen M, Reinecker HC, Witthoft T, Voss A, Schreiber S, Raedler A (1993) Enhanced secretion of TNF-α, IFN-γ, IL-1β and IL-6 bylamina propriamononuclear cells from patients with inflammatory bowel disease In: J Scholmerich, W Kruis, H Goebell, W Hohenberger, V Gross (eds):Inflammatory bowel diseases. Pathophysiology as basis of treatment. Kluwer Academic, Dordrecht, Netherlands, 490

    Google Scholar 

  102. Nicholls S, Stephens S, Braegger CP, Walker-Smith J-A, MacDonald TT (1993) Cytokines in stools of children with inflammatory bowel disease or infective diarrhoea. JClin Pathol46: 757–760

    Article  PubMed  CAS  Google Scholar 

  103. van Lanschot JJB, Mealy K, Wilmore DW (1990) The effects of tumour necrosis factor on intestinal structure and metabolism.Ann Surg212: 663–670

    Article  PubMed  Google Scholar 

  104. Ligumsky M, Simon PL, Karmeli F, Rachmilewitz D (1990) Role of interleukin-1 in inflammatory bowel disease — enhanced production during active disease.Gut31: 686–689

    Article  PubMed  CAS  Google Scholar 

  105. Pullman WE, Elsbury S, Kobayashi M, Hapel AJ, Doe WF (1992) Enhanced mucosal cytokine production in inflammatory bowel disease.Gastroenterology102: 529–537

    PubMed  CAS  Google Scholar 

  106. Stevens C, Walz G, Singaram C, Lipman, ML, Zanker B, Muggia A, Antonioli D, Peppercorn MA, Strom TB (1992) Tumor necrosis factor-alpha, interleukin-1 beta and interleukin-6 expression in inflammatory bowel disease.Dig Dis Sci37: 818–826

    Article  PubMed  CAS  Google Scholar 

  107. Yahida YR, Ceska M, Effenberger F, Kurlak L, Lindley I, Hawkey CJ (1992) Enhanced synthesis of neutrophil-activating peptide-1/interleukin-8 in active ulcerative colitis.Clin Sci82: 273–275

    Google Scholar 

  108. Koizumi M, King N, Lobb R, Benjamin C, Podolsky DK (1992) Expression of vascular adhesion molecules in inflammatory bowel disease.Gastroenterology103: 840–847

    PubMed  CAS  Google Scholar 

  109. Kvale D, Krajci P, Brandzaeg P (1992) Expression and regulation of adhesion molecules ICAM-1 (CD45) and LFA-3 (CD58) in human intestinal epithelial cell lines.Scand J Immunol35: 669–676

    Article  PubMed  CAS  Google Scholar 

  110. Middleton SJ, Shorthouse M, Hunter JO (1993) Increased nitric oxide synthesis in ulcerative colitis.Lancet341: 465–466

    Article  PubMed  CAS  Google Scholar 

  111. Ward PS, Woodger SR, Bodmer M, Foulkes R (1993) Anti-tumour necrosis factor-a monoclonal antibodies (anti-TNF Mab) are therapeutically effective in a model of colonic inflammation.Br J Pharmacol 110:77

    Article  Google Scholar 

  112. Watkins PE, Warren BF, Stephens S, Ward P, Foulkes R (1997) Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alpha.Gut40: 628–633

    PubMed  CAS  Google Scholar 

  113. Stack WA, Mann SD, Roy AJ, Heath P, Sopwith M, Freeman J, Holmes G, Long R, Forbes A, Kamm MA (1997) Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn’s disease [see comments].Lancet349: 521–524

    Article  PubMed  CAS  Google Scholar 

  114. van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, Woody J (1995) Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).Gastroenterology109: 129–135

    Article  PubMed  Google Scholar 

  115. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group.N Engl J Med337: 1029–1035

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Celltech Chiroscience, 216 Bath Road, Slough Berkshire, SL1 4EN, UK

    Amanda Suitters & Roly Foulkes

Authors
  1. Amanda Suitters
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roly Foulkes
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Celltech Chiroscience, 216 Bath Road, Slough Berkshire, SL1 4EN, UK

    Gerry A. Higgs

  2. Cellular Microbiology Research Group Eastman Dental Institute, University College London, 256 Gray’s Inn Road, London, WC1X 8LD, UK

    Brian Henderson

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer Basel AG

About this chapter

Cite this chapter

Suitters, A., Foulkes, R. (2000). Cytokine-neutralizing therapeutic antibodies. In: Higgs, G.A., Henderson, B. (eds) Novel Cytokine Inhibitors. Progress in Inflammation Research. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8450-1_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-8450-1_6

  • Publisher Name: Birkhäuser, Basel

  • Print ISBN: 978-3-0348-9572-9

  • Online ISBN: 978-3-0348-8450-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation